IPD

Impedimed

Health Care Equipment & Services

Impedimed is a global leader in medical technology, specializing in the development and sale of devices using bioimpedance spectroscopy for noninvasive clinical assessment. The company focuses on addressing the challenges of secondary lymphedema, particularly related to breast cancer, through innovative solutions like the SOZO® Digital Health Platform. With operations in the US, Europe, and Austra...

Health Care

Medical Devices

Bioimpedance

Lymphedema

Shorted

short percentage0.61%

reported shorts12.4M

shares on issue2.039B

About

website

impedimed.com

industry

Health Care Equipment & Services

address

Unit 1, 50 Parker Court, PINKENBA, QLD, AUSTRALIA, 4008

Connect

Key Metrics

market cap

$36.70M

eps$-0.01

More Health Care Equipment & Services Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Health Care

Medical Devices

Bioimpedance

Lymphedema

ASX

Company Overview

AI-generated company summary

Company History

Impedimed was founded with the mission to revolutionize care through fluid and body composition analytics. Over the years, it has grown into a leading medical technology company listed on the Australian Stock Exchange. The company has achieved significant milestones, including the development of the FDA-cleared SOZO® platform, which has set new standards in the early detection and management of lymphedema. Impedimed continues to expand its global presence and product offerings.

Competitive Advantages

Impedimed's competitive advantages include its proprietary bioimpedance spectroscopy technology, which is FDA-cleared for clinical use, and its focus on noninvasive solutions for lymphedema management. The company's SOZO® platform offers a unique, cloud-based solution that enhances patient care and sets new standards in the industry.

Risk Factors

•Regulatory changes affecting medical device approvals
•Market competition from other healthcare technology companies
•Dependence on successful product innovation and adoption

Recent Developments

Last 6 months

In the past six months, Impedimed has announced the discontinuation of certain products, such as the L-Dex® U400 and DF50, as part of its strategy to focus on more advanced solutions like the SOZO® platform.

Key People

Leadership team at Impedimed

Parmjot Bains, MD

Managing Director & CEO

Parmjot Bains is the Managing Director and CEO of Impedimed, leading the company with a focus on innovation and patient outcomes.

McGregor Grant, BEc, CA, GAICD, FGIA, FCIS

Executive Director & CFO

McGregor Grant serves as the Executive Director and CFO, bringing extensive financial and strategic expertise to Impedimed.

Financial Reports

18 reports available

Quarterly Activities Report and Appendix 4C - Sep-2025 Qtr

Quarterly ReportOct 30, 2025via asx_announcements

Appendix 4E

Annual ResultsAug 28, 2025via asx_announcements

2025 Annual Report

Annual ReportAug 28, 2025via asx_announcements

Quarterly Activities Report and Appendix 4C - Jun-2025 Qtr

Quarterly ReportJul 31, 2025via asx_announcements

Quarterly Activities Report and Appendix 4C - Mar-2025 Qtr

Quarterly ReportApr 30, 2025via asx_announcements

Appendix 4D and Interim Financial Report

Half Year ResultsFeb 26, 2025via asx_announcements

Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr

Quarterly ReportJan 31, 2025via asx_announcements

Quarterly Activities Report and Appendix 4C - Sep-2024 Qtr

Quarterly ReportOct 22, 2024via asx_announcements

2024 Annual Report

Annual ReportAug 29, 2024via asx_announcements

Appendix 4E

Annual ResultsAug 29, 2024via asx_announcements

Showing 10 of 18 reports